Table 3.
Sensitivity analysis for medication adherences according to age and numbers of medications
| ARB-only group (n=29 400) |
CCB-only group (n=58 401) |
MPC group (n=10 458) |
SPC group (n=18 418) |
P value* | MPR differences† | P value‡ | |||||
| Crude MPR mean | Adjusted MPR mean§ (95% CI) | Crude MPR mean | Adjusted MPR mean§ (95% CI) | Crude MPR mean | Adjusted MPR mean§ (95% CI) | Crude MPR mean | Adjusted MPR mean§ (95% CI) | ||||
| 20–49 years (n=24 957) | |||||||||||
| 1–2 (n=6827) | 76.7 | 76.6 (75.6 to 77.6) | 75.8 | 74.7 (73.4 to 76.0) | 82.3 | 84.1 (80.2 to 88.0) | 83.4 | 84.8 (83.4 to 86.1) | <0.01 | 0.7 | 0.78 |
| 3–4 (n=11 768) | 78.2 | 78.5 (77.6 to 79.3) | 78.6 | 77.5 (76.8 to 78.3) | 85.6 | 86.7 (85.2 to 88.2) | 83.9 | 85.1 (84.1 to 86.1) | <0.01 | −1.6 | 0.01 |
| 5–6 (n=4595) | 78.1 | 78.6 (77.4 to 79.8) | 76.7 | 75.3 (74.0 to 76.6) | 82.2 | 83.9 (81.6 to 86.3) | 84.2 | 85.3 (83.5 to 87.0) | <0.01 | 1.3 | 0.70 |
| 7–9 (n=1360) | 79.4 | 79.3 (76.9 to 81.2) | 77.5 | 76.7 (74.1 to 79.4) | 76.7 | 78.6 (74.5 to 82.7) | 81.9 | 82.4 (79.0 to 85.8) | <0.01 | 3.8 | 0.13 |
| ≥9 (n=407) | 68.7 | 67.1 (62.6 to 71.6) | 72.4 | 68.0 (63.1 to 73.0) | 73.2 | 81.4 (74.0 to 88.8) | 86.5 | 89.8 (82.4 to 97.1) | <0.01 | 8.4 | 0.05 |
| 50–64 years (n=46 085) | |||||||||||
| 1–2 (n=7933) | 81.8 | 81.9 (81.0 to 82.9) | 81.4 | 81.0 (80.1 to 81.9) | 88.9 | 89.2 (85.6 to 92.9) | 88.5 | 89.3 (87.8 to 90.7) | <0.01 | 0.1 | 0.45 |
| 3–4 (n=20 396) | 82.5 | 83.0 (82.4 to 83.6) | 83.2 | 82.3 (81.9 to 82.8) | 88.3 | 89.5 (88.3 to 90.6) | 89.1 | 90.4 (89.6 to 91.2) | <0.01 | 0.9 | 0.72 |
| 5–6 (n=11 657) | 83.5 | 83.7 (83.0 to 84.4) | 83.8 | 83.2 (82.6 to 83.9) | 87.8 | 88.5 (87.3 to 89.8) | 90.3 | 91.1 (90.0 to 92.1) | <0.01 | 2.5 | <0.01 |
| 7–9 (n=4438) | 83.4 | 83.4 (82.2 to 84.5) | 82.5 | 80.4 (79.2 to 81.5) | 81.9 | 85.1 (83.1 to 87.1) | 89.9 | 92.3 (90.6 to 94.0) | <0.01 | 7.2 | <0.01 |
| ≥9 (n=1661) | 79.2 | 78.8 (76.9 to 80.6) | 81.5 | 78.7 (76.7 to 80.8) | 78.2 | 83.4 (80.3 to 86.4) | 89.6 | 91.3 (88.3 to 94.3) | <0.01 | 7.9 | <0.01 |
| 65–74 years (n=30 652) | |||||||||||
| 1–2 (n=3412) | 81.3 | 82.5 (80.6 to 84.4) | 81.1 | 80.3 (79.2 to 81.4) | 88.8 | 91.1 (85.5 to 96.8) | 88.9 | 91.0 (88.3 to 93.8) | <0.01 | −0.1 | 0.94 |
| 3–4 (n=11 308) | 83.5 | 83.9 (83.0 to 84.8) | 83.0 | 82.5 (81.9 to 83.1) | 88.7 | 89.2 (87.5 to 90.9) | 90.3 | 91.6 (90.3 to 92.9) | <0.01 | 2.4 | 0.03 |
| 5–6 (n=9267) | 83.1 | 83.1 (82.3 to 84.0) | 82.7 | 82.3 (81.6 to 83.0) | 88.0 | 88.3 (86.8 to 89.8) | 91.5 | 92.5 (91.2 to 93.8) | <0.01 | 4.2 | <0.01 |
| 7–9 (n=4562) | 81.3 | 81.7 (80.5 to 82.9) | 81.7 | 80.4 (79.3 to 81.5) | 85.4 | 87.4 (85.4 to 89.4) | 90.8 | 92.5 (90.7 to 94.4) | <0.01 | 5.2 | <0.01 |
| ≥9 (n=2103) | 79.8 | 79.3 (77.5 to 81.1) | 79.1 | 77.1 (75.4 to 81.1) | 78.6 | 83.1 (79.9 to 86.2) | 90.2 | 92.5 (89.5 to 95.6) | <0.01 | 9.5 | <0.01 |
| ≥75 years (n=14 983) | |||||||||||
| 1–2 (n=1351) | 80.6 | 81.0 (77.1 to 84.9) | 75.7 | 75.5 (73.8 to 77.3) | 82.4 | 83.1 (72.1 to 94.0) | 85.4 | 85.9 (80.3 to 91.5) | <0.01 | 2.9 | 0.69 |
| 3–4 (n=4916) | 79.2 | 80.4 (78.7 to 82.1) | 78.5 | 77.9 (77.0 to 78.9) | 85.2 | 85.6 (82.6 to 88.6) | 87.4 | 88.8 (86.3 to 91.2) | <0.01 | 3.2 | 0.42 |
| 5–6 (n=4586) | 79.8 | 80.5 (79.0 to 82.0) | 77.4 | 76.5 (75.4 to 77.6) | 83.4 | 85.2 (82.6 to 87.8) | 88.7 | 90.4 (87.9 to 92.8) | <0.01 | 5.2 | 0.01 |
| 7–9 (n=2711) | 79.3 | 79.6 (77.9 to 81.4) | 76.8 | 75.8 (74.3 to 77.2) | 83.1 | 85.3 (82.3 to 88.2) | 87.6 | 89.4 (86.4 to 92.3) | <0.01 | 4.1 | 0.18 |
| ≥9 (n=1419) | 77.8 | 77.4 (75.1 to 79.7) | 75.5 | 74.9 (72.8 to 77.0) | 80.2 | 81.3 (77.1 to 85.4) | 85.7 | 88.6 (84.2 to 93.0) | <0.01 | 7.4 | 0.06 |
Analyses were performed using ANCOVA.
*P value of crude MPR mean.
†MPR differences=adjusted MPR of SPC group – adjusted MPR of MPC group.
‡P value of MPR differences.
§Adjusted for factors associated with the patient (age, sex), condition (comorbidity), therapy (drug costs, number of concurrent drugs, prescription period), the healthcare system (insurance coverage) and the social/economic status (income, residence).
ANCOVA, analysis of covariance; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers; MPC, multiple-pill combination; MPR, medication possession ratio; SPC, single-pill combination.